What Is Methenamine Hippurate and How Does It Work?

Methenamine hippurate is a urinary antiseptic that works as a prodrug, meaning it does nothing useful until it reaches the bladder. Once there, acidic urine breaks it down into formaldehyde, a potent, nonspecific killer of bacteria. It has been used to prevent recurrent urinary tract infections for well over a century, and recent clinical trials have revived interest in it as a genuine alternative to long-term preventive antibiotics.

A Prodrug That Becomes Formaldehyde

Methenamine hippurate is a salt made up of two components: methenamine (also called hexamethylenetetramine) and hippuric acid. The methenamine portion is the active ingredient. When it reaches urine that is sufficiently acidic, a chemical reaction called hydrolysis splits the methenamine molecule apart, releasing formaldehyde and ammonia. Formaldehyde is the part that actually kills bacteria. It works by denaturing proteins and nucleic acids in bacterial cells, which is a blunt, nonspecific mechanism that doesn’t care what species of bacterium it encounters.

The hippuric acid half of the pill serves a supporting role. Because the whole process depends on acidic urine, the hippuric acid is meant to help lower urinary pH and create conditions favorable for formaldehyde release. However, clinical evidence on whether the hippuric acid component actually lowers urine pH by a meaningful amount is mixed. One study of patients treated for infected kidney stones found that methenamine hippurate at a standard dose did not produce a statistically significant reduction in urinary pH, while ammonium chloride did.¹ This means the drug’s pH-lowering effect on its own may be modest, and some clinicians recommend dietary or supplemental acidification alongside it.

Why Urine pH Matters So Much

The conversion of methenamine to formaldehyde is heavily dependent on how acidic the urine is. At a pH of 5.0 (quite acidic), the half-life of methenamine conversion is roughly 20 hours, meaning formaldehyde is generated at a reasonable pace. But at a pH of 6.5 (closer to neutral), that half-life balloons to around 400 hours, a roughly twentyfold increase.² In practical terms, if your urine isn’t acidic enough, most of the methenamine you swallow will pass through your body without ever turning into the formaldehyde that kills bacteria. That same study found that bactericidal concentrations of formaldehyde (the amount actually needed to kill pathogens) could be reached within about three hours in urine at pH 6.0, but maintaining the urine below pH 6 appears critical for the drug to work well.

Work using an in vitro model simulating the urinary tract confirmed this threshold. Formaldehyde concentrations high enough to produce a measurable antibacterial effect were achievable when urine pH was kept at or below about 5.85, and a two-hour exposure to that level of formaldehyde was enough to start killing bacteria.³ This pH sensitivity explains why some patients respond well to methenamine hippurate while others find it ineffective. It also explains why clinicians sometimes advise patients to acidify their urine with vitamin C, cranberry products, or other strategies, though the evidence that vitamin C alone meaningfully lowers urine pH is itself limited.

How the Body Handles It

After you take a dose of methenamine hippurate, the methenamine is absorbed from the gut and reaches peak blood levels within one to two hours. It distributes widely through the body at a volume similar to total body water. The kidneys then efficiently filter it out, which is exactly the point: you want the drug concentrated in the urine, not floating around in the bloodstream. About 80 percent of the dose ends up in the urine within 12 hours.⁴ The blood half-life is roughly four hours. Because the drug is cleared so quickly, the standard dosing schedule is one gram taken twice a day, keeping a steady supply of methenamine arriving in the bladder.

This efficient kidney excretion is both a strength and a limitation. It means the drug concentrates where you need it, in the urinary tract, without accumulating to high levels elsewhere. But it also means that people with significantly impaired kidney function may not excrete enough methenamine into the urine for it to work. Studies have not evaluated the safety of methenamine in patients with severely reduced kidney function.⁵

No Risk of Antibiotic Resistance

One of the most compelling reasons methenamine hippurate has attracted renewed attention is that it doesn’t promote bacterial resistance. Traditional antibiotics target specific bacterial processes, such as cell wall assembly or protein synthesis. Bacteria can evolve mutations or acquire genes that dodge those specific attacks, and that’s exactly what has happened on a massive scale with commonly used UTI antibiotics. Methenamine sidesteps this problem entirely. The formaldehyde it releases damages bacterial proteins and DNA in a nonspecific way, essentially acting as a chemical disinfectant inside the bladder. There’s no single target for bacteria to evolve resistance against.⁵ This makes it a fundamentally different kind of tool. While antibiotics are precision weapons that bacteria can learn to evade, formaldehyde is more like a general-purpose toxin that bacteria cannot easily develop defenses against.

This matters because recurrent UTIs are extremely common, especially in women, and the standard approach of taking a low dose of antibiotics every day for months or years carries a real risk of breeding resistant organisms. Each course of preventive antibiotics creates selection pressure on the bacteria living in and around the urinary tract, gut, and vaginal flora. Resistance to trimethoprim, one of the most commonly prescribed UTI preventives, has risen sharply in many parts of the world. Methenamine hippurate offers a way to reduce the number of infections without contributing to this resistance spiral.

How It Performed in a Major Clinical Trial

The most important recent evidence for methenamine hippurate comes from the ALTAR trial, a large randomized trial conducted across multiple centers in the United Kingdom. The trial enrolled women with recurrent UTIs and compared 12 months of methenamine hippurate (one gram twice daily) against 12 months of standard low-dose prophylactic antibiotics. The primary question was whether methenamine hippurate was “non-inferior” to antibiotics, meaning it performed well enough that the difference was clinically acceptable even if it wasn’t identical.

The results showed that women taking methenamine hippurate experienced about 1.38 UTI episodes per person-year, compared with 0.89 episodes per person-year in the antibiotic group. That’s a difference of roughly half an extra UTI per year in the methenamine group. Crucially, this difference fell within the trial’s predefined non-inferiority margin of one additional UTI per person-year, allowing the researchers to conclude that methenamine hippurate was non-inferior to antibiotics for preventing recurrent UTIs.⁶ In other words, methenamine hippurate performed well enough that the small difference in infection rates was acceptable, especially given the trade-off of avoiding long-term antibiotic use.

It’s worth noting what “non-inferior” means in practice. The women on methenamine hippurate did experience slightly more UTIs than those on antibiotics. So this isn’t a case of the drug being “just as good” in every measurable way. The argument for switching is that a modest increase in UTI episodes is a reasonable price to pay for eliminating months of antibiotic exposure and the resistance that comes with it.

Cost-Effectiveness

An economic analysis conducted alongside the ALTAR trial found that methenamine hippurate was, on average, slightly less expensive and marginally more effective in terms of quality-adjusted life years compared with antibiotic prophylaxis. The average cost saving was about £40 per patient over the trial period. The probability of methenamine hippurate being considered cost-effective ranged from 51 to 67 percent depending on how much value was placed on each additional unit of quality of life.⁷ Those numbers look borderline on their own, but the analysis also noted that methenamine hippurate became more clearly cost-effective when the broader benefits of reduced antibiotic use were factored in. Antibiotic resistance carries enormous societal costs that a standard economic model for one patient doesn’t capture.

Hippurate Versus Mandelate

Methenamine hippurate isn’t the only formulation of methenamine that has been used clinically. Methenamine mandelate, which pairs methenamine with mandelic acid instead of hippuric acid, was the more commonly used version in earlier decades. Both formulations rely on the same active mechanism: methenamine reaching the bladder and being hydrolyzed into formaldehyde. The difference lies in the accompanying organic acid.

Laboratory testing comparing the two has produced an interesting wrinkle. At a pH of 5.5, methenamine hippurate was actually found to be less active than methenamine alone, while methenamine mandelate was about as active as the parent compound on its own.⁸ This finding suggests the hippuric acid component might slightly interfere with the drug’s antibacterial activity in a controlled lab setting, even if it’s intended to help with pH. In clinical practice, methenamine hippurate has become the more widely prescribed version in many countries, partly because of better tolerability and partly because it’s the formulation that has been studied in the most recent large trials. But it’s a legitimate question whether mandelic acid might actually be the better partner molecule. The clinical trial data comparing the two head-to-head in real patients is thin.

Safety and Side Effects

Methenamine hippurate is generally well tolerated. The most common side effects involve the gastrointestinal tract: nausea, stomach upset, and occasionally diarrhea. Skin rashes have been reported but are uncommon. Because the drug produces formaldehyde in the bladder, some patients experience bladder irritation, especially at higher doses or if urine is very acidic. Serious adverse events are rare. The ALTAR trial did not report significant safety concerns over its 12-month treatment period.

The drug is contraindicated in patients with severe kidney impairment, as its mechanism depends entirely on renal excretion into the urine, and the safety in that population hasn’t been studied.⁵ It’s also generally avoided in patients with severe liver disease, since formaldehyde is metabolized by the liver. Patients with severe dehydration should be cautious, as concentrated formaldehyde in a small volume of urine could irritate the bladder lining more than usual.

One important practical detail: methenamine hippurate is a preventive drug, not a treatment for an active UTI. It works by maintaining a low level of formaldehyde in the bladder to keep bacterial populations from gaining a foothold. If you already have a full-blown infection with symptoms like burning, urgency, and fever, you need an antibiotic to treat the existing infection. Methenamine hippurate is what you take afterward to try to stop the next one from happening.

Who Benefits Most

The clearest evidence supports methenamine hippurate for women with recurrent uncomplicated UTIs, which is the population studied in the ALTAR trial. “Recurrent” in this context typically means two or more infections in six months or three or more in a year. For these patients, the choice is usually between long-term low-dose antibiotics and something else, and methenamine hippurate is the strongest “something else” currently available.

Evidence also suggests it can be useful in older adults with recurrent UTIs, a population where antibiotic resistance is a particularly acute concern because of frequent healthcare contact and prior antibiotic exposure.⁵ The drug has also been studied in the context of preventing infections after genitourinary surgery, where a short course can reduce the risk of postoperative UTI.

Where the evidence gets thinner is in populations with complicated urinary tract anatomy, such as people with neurogenic bladders, indwelling catheters, or structural urinary tract abnormalities. These patients often have chronically alkaline urine or other factors that make the pH-dependent mechanism less reliable. Some clinicians still try methenamine hippurate in these settings, but the data supporting its use there is weaker, and managing urine pH becomes even more important and difficult.

Practical Tips for Getting the Most Out of It

Because the drug’s effectiveness hinges on urine acidity, patients who want methenamine hippurate to work optimally should pay attention to their diet and fluid intake. Foods that tend to acidify urine include meat, fish, eggs, and grains. Foods that alkalinize urine include most fruits and vegetables (with the notable exceptions of cranberries and plums). Drinking large volumes of fluid is generally healthy for the urinary tract, but excessive fluid intake can dilute both the methenamine and the formaldehyde in the bladder, potentially reducing effectiveness.

The standard dose is one gram taken twice daily, and consistency matters. Because the blood half-life is only about four hours and the drug is cleared rapidly by the kidneys, missing doses means gaps in formaldehyde coverage in the bladder. Taking it at regular 12-hour intervals helps maintain steady urinary levels.

Patients should also be aware that methenamine hippurate can interact with certain medications. It should not be combined with sulfonamide antibiotics, as formaldehyde can form an insoluble precipitate with sulfonamides in the urine, potentially causing crystal formation. This interaction was documented decades ago and remains a standard caution in prescribing guidelines.

A Drug From 1894 That Still Has Relevance

Methenamine was first introduced into clinical medicine in 1894 by Arthur Nicolaier, making it one of the oldest antimicrobial agents still in use.⁹ For most of the twentieth century it was a workhorse of UTI prevention. When modern antibiotics arrived and proved so effective at treating acute infections, methenamine was gradually sidelined. Why bother with a finicky prodrug that depends on urine pH when you could just prescribe trimethoprim or nitrofurantoin?

The answer, as it turns out, is antibiotic resistance. The same effectiveness that made antibiotics the default option for UTI prevention has eroded their reliability through overuse. Resistance rates to first-line UTI antibiotics have climbed steadily, and clinicians are increasingly looking for non-antibiotic strategies to break the cycle. Methenamine hippurate fits this niche well. It isn’t perfect, it requires attention to urine pH, and the infection reduction it offers is slightly less than what long-term antibiotics achieve. But it avoids the resistance problem entirely, costs about the same or less, and has a safety profile built on more than a century of human use. For a drug that predates the discovery of penicillin by several decades, that is a remarkably strong case for continued clinical relevance.